Article
Envision Pharma Group
Translating Discovery: Shaping Tomorrow’s Prostate Cancer Therapies
Clips
Summary
In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Dr. Monty Pal welcomes Dr. Tanya Dorff, professor in the Department of Medical Oncology & Therapeutics Research and section chief of the Genitourinary Disease Program at City of Hope.
Together they dive into Dorff’s pioneering work in immunotherapy for prostate cancer - from the challenges of moving treatments from bench to bedside, to the importance of collaborative team-science, and the role of deep biological correlates in informing future studies. Beyond her clinical and research achievements, Dr. Dorff reflects on mentorship, work-life balance, and the importance of supporting diversity of thought in academic medicine. She shares how creative pursuits help her recharge and offers advice for aspiring oncologists to pursue their passions and embrace bold leaps at the edge of breakthrough.
Tune in to discover how clinical innovation, collaboration, and a patient-centered approach are the secret sauce driving advances in cancer care.
Related Topics
You May Also Like
Envision Pharma Group
Article
Rajat Thawani, Neha Agrawal, Nicholas F Taflin, Adel Kardosh, Emerson Y Chen
Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer
Article
Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry and Jorge Nieva
Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials
Article
S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar
New Realities of Phase I Clinical Trials in the Era of
Article
Louis Everest, BSc; Monica Shah, BSc; Kelvin K.W. Chan, MD, MSc, PhD
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
Article
G. Pentheroudakis